Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing of radium-223 and docetaxel in symptomatic bone-only mCRPC
2016-004452-29Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of radium-223 dichloride, docetaxel and prednisone in metastatic castration-resistant prostate cancer (mCRPC) and prostate adenocarcinoma (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: QoL clinical benefit. Started Sep 2018; status: active.
02
Drugs
radium-223 dichloridedocetaxelprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate adenocarcinoma
Beyond the preview
Go deeper on 2016-004452-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004452-29.